Lyrinex
Pregabalin INN

Lyrinex (Pregabalin) is a structural derivative of the inhibitory neurotransmitter gamma-amino butyric acid (GABA). It does not bind directly to $GABA_A$, $GABA_B$, or benzodiazepine receptor. **Lyrinex** (Pregabalin) binds with high affinity to the alpha-2-delta site (an auxiliary subunit of voltage-gated calcium channels) in central nervous system tissues. Oral bioavailability of **Lyrinex** (Pregabalin) is ≥90% and is independent of dose. It is eliminated from the systemic circulation primarily by renal excretion as unchanged drug with a mean elimination half-life of 6.3 hours in subjects with normal renal function.

COMPOSITION
Lyrinex 50 Capsule: Each capsule contains Pregabalin INN 50 mg.
Lyrinex 75 Capsule: Each capsule contains Pregabalin INN 75 mg.
Lyrinex 150 Capsule: Each capsule contains Pregabalin INN 150 mg.

INDICATION
Lyrinex (Pregabalin) is indicated for:
- Management of neuropathic pain associated with diabetic peripheral neuropathy
- Management of post-herpetic neuralgia
- Adjunctive therapy for adult patients with partial onset seizures
- Management of fibromyalgia
- Neuropathic pain associated with spinal cord injury.

DOSAGE & ADMINISTRATION
Neuropathic pain associated with diabetic peripheral neuropathy: The maximum recommended dose of **Lyrinex** (Pregabalin) is 100 mg three times a day (300 mg/day) in patients with creatinine clearance of at least 60 mL/min. Dosing should begin at 50 mg three times a day (150 mg/day) and may be increased to 300 mg/day within 1 week based on efficacy and tolerability.

Post-herpetic neuralgia: The recommended dose of **Lyrinex** (Pregabalin) is 75 to 150 mg two times a day, or 50 to 100 mg three times a day (150 to 300 mg/day) in patients with creatinine clearance of at least 60 mL/min. Dosing should begin at 75 mg two times a day, or 50 mg three times a day (150 mg/day) and may be increased to 300 mg/day within 1 week based on efficacy and tolerability.

Adjunctive therapy for adult patients with partial onset seizures: In general, it is recommended that patients be started on a total daily dose no greater than 150 mg/day (75 mg two times a day, or 50 mg three times a day). Based on individual patient response and tolerability, the dose may be increased to a maximum dose of 600 mg/day.

Management of Fibromyalgia: The recommended dose of **Lyrinex** (Pregabalin) for fibromyalgia is 300 to 450 mg/day. Dosing should begin at 75 mg two times a day (150 mg/day) and may be increased to 150 mg two times a day (300 mg/day) within 1 week based on efficacy and tolerability.

Neuropathic pain associated with spinal cord injury: The recommended dose range is 150 to 600 mg/day. The recommended starting dose is 75 mg two times a day (150 mg/day). The dose may be increased to 150 mg two times a day (300 mg/day) within 1 week based on efficacy and tolerability.

Lyrinex (Pregabalin) capsules can be taken without regards to meals.

Lyrinex (Pregabalin) dosage adjustment based on renal function:

Creatinine Clearance (mL/min)	Total Lyrinex (Pregabalin) Daily Dose (mg/day)*				Dose Regimen
60	150	300	450	600	BID or TID
30–60	75	150	225	300	BID or TID
15–30	25-50	75	100-150	150	QD or BID
<15	25	25-50	50-75	75	QD

TID = Three divided doses; BID = Two divided doses; QD = Single daily dose.
*Total daily dose (mg/day) should be divided as indicated by dose regimen to provide mg/dose.

SIDE EFFECT
The most common side effects include dizziness, somnolence, dry mouth, edema, blurred vision, weight gain and abnormal thinking.

PRECAUTION
Discontinuation of **Lyrinex** (Pregabalin) without tapering may produce insomnia, nausea, headache and diarrhea. So it should be tapered gradually over a minimum of 1 week rather than discontinued abruptly. Creatinine kinase may be elevated if treated with **Lyrinex** (Pregabalin). It should be discontinued rapidly if myopathy is diagnosed or suspected or if creatinine kinase is elevated markedly.

CONTRAINDICATION
Lyrinex (Pregabalin) is contraindicated in patients with known hypersensitivity to **Lyrinex** (Pregabalin) or any of its components.

DRUG INTERACTION
There are no significant interactions between **Lyrinex** (Pregabalin) with other antiepileptic drugs & oral contraceptive. **Lyrinex** (Pregabalin) may potentiate the effects of ethanol and lorazepam.

USE IN PREGNANCY AND LACTATION
Pregnancy category of **Lyrinex** (Pregabalin) is C. So it should only used if potential benefit justifies the potential risks to the fetus.

Pregabalin may be secreted through the breast milk like other drugs, so it should be used in nursing women only if the benefits clearly overweigh the risk.

PAEDIATRIC USE
The safety and efficacy of **Lyrinex** (Pregabalin) in paediatric patients have not been established.

STORAGE CONDITION
Keep in a cool & dry place (below 30^{o} C), protected from light & moisture. Keep out of the reach of children.

HOW SUPPLIED
Lyrinex 50 Capsule: Each box contains 30 capsules in Alu-Alu blister packs.
Lyrinex 75 Capsule: Each box contains 30 capsules in Alu-Alu blister packs.
Lyrinex 150 Capsule: Each box contains 20 capsules in Alu-Alu blister packs.

NIPRO JMI Pharma

Manufactured by:
NIPRO JMI Pharma Ltd.
Chauddagram, Comilla, Bangladesh.